QM · rank #5 · 2026-07-21
LQDA
NASDAQ · $6.69B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +439.64% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +28.2% |
| Profit margin Net profit margin, trailing 12 months. | +7.7% |
| Market cap (USD) Size filter: > $500M required. | $6.69B |
| Anchor (recent) Close on 2026-06-18 | $71.07 |
| Anchor (far) Close on 2025-06-20 | $13.17 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies commercializes YUTREPIA, an FDA-approved dry-powder inhaled treprostinil for PAH and PH-ILD, competing directly against United Therapeutics' Tyvaso franchise with a differentiated device and dosing profile.
Rationale
The quality_momentum signal is reinforced by three consecutive profitable quarters, 44% sequential revenue growth in Q1 2026, a positive ROE of 28%, and ~23% inhaled prostacyclin share still expanding — momentum is fundamental, not sentiment-driven.
Material risks
- 1Single-product concentration in YUTREPIA means any United Therapeutics competitive response (pricing, label expansion, or new formulation) or a reimbursement/formulary setback could rapidly compress the revenue base with no offsetting product to cushion the blow.
- 2Consensus projects a meaningful sequential revenue step-down (~$110M vs. $132.9M Q1 actuals) for Q2 2026, suggesting the market anticipates normalization or pull-forward effects, which could stall the momentum signal if growth decelerates faster than expected.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.